The importance of pharmacogenetics in the treatment of breast cancer - a literature review
DOI:
https://doi.org/10.33448/rsd-v10i15.23162Keywords:
OncologyAbstract
In view of the reports on the use of germline genetic information in preventive and treating this type of carcinoma, as well as their potential as patterns of genetic markers analogous to expression profiles obtained from tumor tissue, allowing a more powerful prediction who will respond best to a specific treatment or regimen. Thus, this study aims to assess the importance of pharmacogenetics in the treatment of breast cancer. This is a literature review, where the following databases were used: MEDLINE, LILACS and Scielo, in which publications in Portuguese and English were selected between 2016 and 2021. Through the results obtained, it was observed that the introduction of pharmacogenetics in oncology has enabled the development of a new generation of pharmacological agents capable of being selective against neoplastic cells, enabling a significant improvement in the risk/benefit ratio of numerous types of cancer, particularly breast cancer. Thus, the role of the pharmacist becomes essential in Pharmacogenetics when associated with clinical practice, as he is a health professional who has a full understanding of the phenomena that occur in this category, contributing to the assistance of other components of the functional health group , performing a plausible interpretation of the analysis results and their subsequent applicability.
References
American Society of Health-System Pharmacists. (2015). ASHP statement on the pharmacist’s role in clinical pharmacogenomics. Am J Health-Syst Pharm, 72, 579-588.
Bray, F, Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Journal for Clinicians, 68(6), 394 - 424.
Carpenter, J. S., Rosenman, M. B., Knisely, M. R., Decker, B. S., Levy, K. D. & Flockhart, D. A. (2016). Pharmacogenomically actionable medications in a safety net health care system. SAGE Open Medicine, 4, 1 - 8.
Carrondo, A. P. (2016). Monitorização terapêutica de fármacos. Revista Ordem Dos Farmacêuticos, 95, 1-2.
Cruz, G. C. (2018). Impacto do polimorfismo CYP2D6*4 em pacientes com câncer de mama em uso do tamoxifeno. Monografia (Graduação) - Universidade Federal do Rio Grande do Norte.
Dong, O. M. & Wiltshire, T. (2017). Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting. Physiological Genomics, 49(7), 346–354.
Drögemöller, B. I., Monzon, J. G., Bhavsar, A. P., Borrie, A. E., Brooks, B., Wright, G. E. B., Liu, G., Renouf, D. J., Kollmannsberger, C. K. & Bedard, P. L. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic effects in adult patients with testicular câncer. Jama Oncology, 3(11), 1558-1562. 10.1001/jamaoncol.2017.0502
Falcetta, F. S., Träsel, H. D. A. V., Almeida, F. K., Falcetta, M. R. R., Falavigna, M. & Rosa, D. D. (2018). Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat, 170(3):455-76.
Iriart, J. A. B. & Caprara, (2011). A. Novos objetos e novos desafios para a antropologia da saúde na contemporaneidade. Physis (Rio J.), 21, 1253-1268.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2018). Incidência, mortalidade e morbidade hospitalar por câncer em crianças, adolescentes e adultos jovens no Brasil: informações dos registros de câncer e do sistema de mortalidade. Rio de Janeiro.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2019). Estimativa 2020: incidência do Câncer no Brasil. Rio de Janeiro: INCA.
Kim, S., Yun, Y. M., Chae, H. J., Cho, H. I. M., Kim, I. S. & Chun, S. (2017). Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical A aplicação da Farmacogenética em contexto de farmácia hospitalar Practice Guidelines. Annals of Laboratory Medicine, 37(2), 180.
Kranzler, H. R, Smith, R. V., Sshnoll, R., Moustafa, A. & Greenstreet-Akman, E. (2017). Precision medicine and pharmacogenetics: What does oncology have that addiction medicine does not? Addiction, 112(12), 2086-2094.
Lazaridis, K. N. (2017). Improving Therapeutic Odyssey: PreemptivePharmacogenomics Utility in Patient Care. Clinical Pharmacology and Therapeutics, 101(1), 39-41.
Lopez-Cortes, A., Guerrero, S. R., Alvarado, A. T. & Quino, L. A. (2017). State of art of cancer pharmacogenomics in Latin American populations. International Journal of Molecular Sciences, 18(6), 1-22.
Mandel, M. N. (2019). Riesgo aumentado de cáncer de mama, ovárico y contralateral para portadoras de mutación BRCA1 y BRCA2. Actualización en la Práctica Ambulatoria, 22(3), 1-2.
Márquez, Y. V. A., Balcázar, I. B. & Aristizábal, F. A. (2016). Tratamiento de cáncer de seno y farmacogenética. Revista Colombiana de Biotecnologia, 18(1), 121 – 134.
Mirsadeghi, S. & Larijani, B. (2017). Personalized medicine: Pharmacogeno mics and drug development. Acta Medica Iranica, 55(3), 150-165.
Moreno, L. S. (2017). O uso de tamoxifeno em pacientes com neoplasia mamária. UNILAGO, 1(1). http://revistas.unilago.edu.br/index.php/revista-medicina/article/view/15
Organização Mundial da Saúde (2021). Câncer de mama: sintomas, tratamentos, causas e prevenção. https://antigo.saude.gov.br/saude-de-a-z/cancer-de-mama#:~:text=Relativamente%20raro%20antes%20dos%2035,forma%20r%C3%A1pida%2C%20outros%2C%20n%C3%A3o.
Pegram, M. D., Pivot, X., Cortes, J., Curigliano, G., Yoon, Y., Lim, J., Song, S. & Hong E. (2019). Abstract P6-17-09: Event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast câncer in neoadjuvant setting. Proceeding of the 2018 San antonio Breast Cancer Symposium, 79(4). 10.1158/1538-7445.SABS18-P6-17-09
Pinho, J. R., Sitmik, R. & Mangueira, C. L. (2014). Personalized medicine and the clinical laboratoru. Eistein 12(3), 366-373.
Rivera, J. G. B., Silva, K. R. P. da, Pantoja, B. M., Miranda, M. A., Silva, M. M. P. da & Oliveira, Oliveira, A. E. M. de. (2021). Estudo do perfil farmacogenético das pacientes com Câncer de Mama na região Amazônica do Brazil. Brazilian Journal of Health Review, 4(3), 11723-11734.
Rosenblatt, M. (2017). The Large Pharmaceutical Company Perspective. New England Journal of Medicine, 376(1), 52–60
Scott, S. A. (2017). Personalizing medicine with clinical pharmacogenetics. Genetics in Medicine, 13(12), 987–995.
Silva, G. A., Castro, N. S. & Figueiredo, R. O. (2020). Mecanismos epigenéticos e a ação da expressão da proteína BRCA na carcinogênese mamária. Brazilian Journal of Development, 6(10), 82596-82613.
Urenã, A. M. & Resenkranz, B. M. (2018). Generalidades de cáncer de mama para médico general. Medicina Legal de Costa Rica, 35(1), 44-51.
Weitzel, K. W., Cavallari, L. H. & Lesko, J. (2017). Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now. Pharmaceutical Research, 34(8), 1551–1555.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Caroline Cardoso Corrêa; Jessica Vanina Ortiz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
